Showing results (1-10 of 166) with videos related to
Sort By:
Pageof 17
British Journal of Clinical Pharmacology|February 1, 1977
Ethical review in the pharmaceutical industryL E Ramsay, M J Tidd, J K Butler, et al.British Journal of Clinical Pharmacology|June 1, 1975
Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responsesL E Ramsay, P Hessian, M J TiddBritish Journal of Clinical Pharmacology|June 1, 1976
The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjectsL E Ramsay, J R Shelton, M J TiddBritish Journal of Clinical Pharmacology|January 6, 2012
Canrenone--the principal active metabolite of spironolactone?L E Ramsay, J R Shelton, D Wilkinson, et al.International Journal of Clinical Pharmacology and Biopharmacy|May 1, 1977
Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspensionM J Tidd, L E Ramsay, J R Shelton, et al.European Journal of Clinical Pharmacology|January 3, 1977
Paradoxical potassium excretion in response to aldosterone antagonistsL E Ramsay, I R Harrison, J R Shelton, et al.Clinical Endocrinology|November 1, 1978
Endocrine effects of spironolactone in manM J Tidd, C E Horth, L E Ramsay, et al.Journal of Pharmaceutical Sciences|October 1, 1977
Factors influencing comparative bioavailability of spironolactone tabletsJ M Clarke, L E Ramsay, J R Shelton, et al.Adverse Drug Reactions and Acute Poisoning Reviews|January 1, 1984
Priorities in the benefit-risk assessment of new drugsG R VenningBritish Medical Journal (Clinical Research Ed.)|January 15, 1983
Identification of adverse reactions to new drugs. I: What have been the important adverse reactions since thalidomide?G R VenningPageof 17